Data from the EVOLVE-1 and EVOLVE-2 phase 3 clinical trials suggest that galcanezumab (Emgality, Eli Lilly) can maintain ≥50% responder rates equivalent to that of placebo while reducing more monthly migraine days for 5 months after halting treatment.
Neurology News Network for the week of April 13, 2019.
The International Headache Society has issued a number of recommendations for the proper design of trials for the prevention of pediatric migraine, hoping to address the challenges which are unique to pediatric patient populations.
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
The director of the Jefferson Headache Center at Jefferson University Hospital discusses the problem with traditional nasal sprays and how improvements in formulation and delivery can improve efficacy.
Neurology Times' podcast with a pediatric headache specialist and neurologist who has performed over 1000 procedures to treat migraine in children and adolescents.
Investigators are looking for and finding new approaches to diagnosis, treatment, and prevention. Here: highlights of some of the latest findings.
Take this brief quiz to test your knowledge of recent recommendations from the American Headache Society for the prevention and acute management of migraine.
Implementing evidence-based practices consistent with the AAN Headache Quality Measures has the potential to improve the quality of care in this patient population, however, additional study is required to determine if better process performance produces better outcomes.
Patients saw significant improvements in help-seeking behaviors and reductions in anxiety that positively correlated with headache load.
Neurology News Network for the week of March 22, 2019.
The migraine specialist spoke to the CGRP receptor antagonist’s potential impact on patients with migraine who have been lacking a novel acute treatment for some time.
Is there a connection between this patient’s ocular symptoms and migraines?
The voucher allows for an expedited 6-month review of the drug’s pending New Drug Application with the FDA.
The director of the Medstar Georgetown University Headache Center spoke about the data that’s been presented thus far, as well as how ubrogepant separates itself from what’s currently available for patients.
After almost a year on the market, post-marketing data has been suggestive of a risk of anaphylaxis and angioedema in patients who are hypersensitive to erenumab or the excipients.
Ned Sharpless, MD, the director of the National Cancer Institute, has been named to the position of acting FDA Commissioner. The announcement was made just a week after the current commissioner, Scott Gottlieb, MD, announced his plans to resign in early April.
This brief slideshow provides concise summaries of key findings in recent studies.
The review period for the oral CGRP receptor antagonist has been set at 10 months, with a Prescription Drug User Fee Act action date in the fourth quarter of 2019.
Neurology News Network for the week of March 9, 2019.
This young woman is otherwise healthy and doesn’t drink or abuse drugs. What’s in your differential diagnosis?
Studies have suggested that exercise may have short- and long-term analgesic effects on migraine. New information has come to light about which type of exercise is best.
The patient has a history of migraine. Is this another attack-or is something else going on?
The 23rd FDA commissioner’s resignation is effective in about a month; his successor has not yet been named.
If approved, galcanezumab would be the first preventive option approved for patients with episodic cluster headache in the United States.
